Benzinga · Oct 2, 2026
Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $150
Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the price target from $88 to $150.
MB
NASDAQ · MBX
MBX Biosciences, Inc. Common Stock
Healthcare · Biotechnology
$56.92
Down-$1.62 (-2.77%)
Updated Oct 7, 2026, 11:29 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 954.72M
- P/E ratio
- -12.07
- Dividend yield
- 0.00%
- 52-week range
- $12.94 – $72.64
- Volume
- 366.63K
- Avg. volume
- 1.44M
Price performance · MBX
MBX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
MBX closed at $56.92 after 21 trading sessions, down 9.64% for the selected period.
- Last close
- $56.92
- Period change
- -9.64%
- Period low
- $53.63
- Period high
- $63.89
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $58.75 | $59.225 | $55.34 | $56.92 | 366.63K |
| Oct 5, 2026 | $58.33 | $59.26 | $56.415 | $58.54 | 583.21K |
| Oct 2, 2026 | $59.28 | $61.12 | $56.90 | $58.51 | 637.32K |
| Oct 1, 2026 | $58.47 | $60.20 | $56.15 | $56.55 | 434.15K |
| Sep 30, 2026 | $58.19 | $59.40 | $56.095 | $58.62 | 523.79K |
| Sep 29, 2026 | $57.27 | $58.24 | $56.55 | $57.75 | 357.12K |
| Sep 28, 2026 | $52.86 | $58.49 | $52.5945 | $57.54 | 439.61K |
| Sep 25, 2026 | $55.83 | $56.00 | $52.32 | $53.63 | 563.53K |
| Sep 24, 2026 | $57.56 | $57.72 | $54.41 | $55.39 | 638.97K |
| Sep 23, 2026 | $61.85 | $61.85 | $57.82 | $57.89 | 352.41K |
| Sep 22, 2026 | $61.14 | $63.45 | $60.84 | $61.98 | 433.37K |
| Sep 21, 2026 | $63.46 | $64.61 | $59.97 | $60.94 | 903.4K |
| Sep 18, 2026 | $64.00 | $64.045 | $61.40 | $62.91 | 932.36K |
| Sep 17, 2026 | $62.50 | $65.00 | $62.50 | $63.89 | 969.81K |
| Sep 16, 2026 | $61.34 | $62.75 | $59.49 | $61.57 | 1.16M |
| Sep 15, 2026 | $58.79 | $61.195 | $58.394 | $61.08 | 652.59K |
| Sep 14, 2026 | $59.35 | $60.22 | $58.87 | $59.49 | 323.68K |
| Sep 11, 2026 | $61.75 | $61.94 | $58.42 | $59.02 | 306.21K |
| Sep 10, 2026 | $62.43 | $63.015 | $60.65 | $60.94 | 457.27K |
| Sep 9, 2026 | $63.29 | $64.04 | $61.285 | $62.91 | 315.69K |
| Sep 8, 2026 | $60.85 | $64.17 | $60.66 | $62.99 | 266.22K |
Latest MBX news
The latest Smart Investors Daily articles mentioning MBX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
MBX research
Overview
Company profile and research snapshot.
Company profile
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $28.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 2, 2026 | Guggenheim | Buy | — |
| Aug 21, 2026 | JP Morgan | Overweight | — |
| Aug 10, 2026 | Truist Securities | Buy | — |
| Jul 29, 2026 | Mizuho | Outperform | — |
| May 12, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 28, 2026
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
SeekingAlpha · Sep 23, 2026
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade)
MBX Biosciences is upgraded to Buy on strong Phase 2 canvuparatide data, Phase 3 path, and cash-rich catalysts. Click for this MBX stock update.
SeekingAlpha · Sep 16, 2026
MBX Biosciences, Inc. (MBX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
MBX Biosciences, Inc. (MBX) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 8:30 AM EDTCompany ParticipantsSteven Hoerter -...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
